Definium Therapeutics

Forecast & Rating18 analysts currently cover Definium Therapeutics, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $71.65, about 82.4% upside from the current price of $39.28. Price targets range from $55.00 to $91.00 — a wide spread, showing clear disagreement over just how much Definium Therapeutics can rise. Historically, about 36.7% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Definium Therapeutics closely still see room for the stock to rise. Data as of Sep 16, 2026; for reference only and not investment advice.